Table of Contents Author Guidelines Submit a Manuscript
Volume 2015, Article ID 195469, 8 pages
Research Article

Hospitalization Events among Children and Adolescents with Sickle Cell Disease in Basra, Iraq

1Center for Hereditary Blood Diseases, Basra Maternity and Children Hospital, Basra, Iraq
2Department of Pediatrics, College of Medicine, University of Basra, Basra, Iraq

Received 22 July 2015; Revised 19 September 2015; Accepted 7 October 2015

Academic Editor: Maria Stella Figueiredo

Copyright © 2015 Zeina A. Salman and Meaad K. Hassan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objectives. Despite improvements in the management of sickle cell disease (SCD), many patients still experience disease-related complications requiring hospitalizations. The objectives of this study were to identify causes of hospitalization among these patients and factors associated with the length of hospital stay (LOS) and readmission. Methods. Data from 160 patients (<14 years old) with SCD who were admitted to the Basra Maternity and Children’s Hospital from the first of January 2012 through July 2012 were analyzed. Results. The main causes of hospitalization were acute painful crises (73.84%), infections (9.28%), acute chest syndrome (8.02%), and acute splenic sequestration crisis (6.32%). The mean LOS was days. The LOS for patients on hydroxyurea ( days) was shorter than that for patients who were not ( days), . The readmission rate (23.1%) was significantly higher among patients with frequent hospitalizations in the previous year (OR 9.352, 95% CI 2.011–43.49), asthma symptoms (OR 4.225, 95% CI 1.125–15.862), and opioid use (OR 6.588, 95% CI 1.104–30.336). Patients on hydroxyurea were less likely to be readmitted (OR 0.082, 95% CI 0.10–0.663). Conclusions. There is a relatively high readmission rate among patients with SCD in Basra. The use of hydroxyurea significantly decreases the LOS and readmission rate.